

(FILE 'HOME' ENTERED AT 09:26:30 ON 23 SEP 2005)

FILE 'EMBASE, BIOSIS, CAPLUS, SCISEARCH, MEDLINE' ENTERED AT 09:26:42 ON  
23 SEP 2005

L1 397 S DEPLET? (W) ?ANTIBOD?  
L2 13157461 S BLOOD OR OR SERUM OR PLASMA OR FLUID  
L3 180 S L1 AND L2  
L4 88 DUPLICATE REM L3 (92 DUPLICATES REMOVED)  
L5 11 S L4 AND (MHC OR HLA)  
L6 559 S REMOV? (W) ?ANTIBOD?  
L7 355 S L6 AND L2  
L8 23 S L7 AND (MHC OR HLA)  
L9 11 DUPLICATE REM L8 (12 DUPLICATES REMOVED)

\* Also reviewed search result from parent 09/809,029

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	10226	magnetic adj bead	US-PGPUB; USPAT	OR	ON	2005/09/23 08:33
L2	20145	mhc or hla	US-PGPUB; USPAT	OR	ON	2005/09/23 08:34
L3	683	1 same 2	US-PGPUB; USPAT	OR	ON	2005/09/23 08:34
L4	56739	purif\$ same antibod\$	US-PGPUB; USPAT	OR	ON	2005/09/23 08:34
L5	594	3 and 4	US-PGPUB; USPAT	OR	ON	2005/09/23 08:34
L6	566	5 and recombinant	US-PGPUB; USPAT	OR	ON	2005/09/23 08:34
L7	3121	2 same recombinant	US-PGPUB; USPAT	OR	ON	2005/09/23 08:34
L8	108	1 same 7	US-PGPUB; USPAT	OR	ON	2005/09/23 08:34
L9	96	4 and 8	US-PGPUB; USPAT	OR	ON	2005/09/23 08:41
L10	1	("5948627").PN.	US-PGPUB; USPAT	OR	OFF	2005/09/23 08:43
L11	1	("5256543").PN.	US-PGPUB; USPAT	OR	OFF	2005/09/23 08:43
L12	1	("5420013").PN.	US-PGPUB; USPAT	OR	OFF	2005/09/23 08:44
L13	1	("5514557").PN.	US-PGPUB; USPAT	OR	OFF	2005/09/23 08:45
L14	1	("6171585").PN.	US-PGPUB; USPAT	OR	OFF	2005/09/23 08:59
L15	34356	transplant or allograft	US-PGPUB; USPAT	OR	ON	2005/09/23 09:00
L16	1443	7 and 15	US-PGPUB; USPAT	OR	ON	2005/09/23 09:00
L17	4827	(remove or deplet or \$deplet\$) near2 (antibod\$3 or immunoglob\$)	US-PGPUB; USPAT	OR	ON	2005/09/23 09:02
L18	261	16 and 17	US-PGPUB; USPAT	OR	ON	2005/09/23 09:02

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	7	mhc-coated or (mhc adj coated) or hla-coated or (hla adj coated)	US-PGPUB; USPAT	OR	ON	2005/09/22 14:19
L2	797700	bead or microsphere or nanosphere or nanoparticle or particle or microparticle	US-PGPUB; USPAT	OR	ON	2005/09/22 14:18
L3	86505	2 and antibod\$3	US-PGPUB; USPAT	OR	ON	2005/09/22 14:19
L4	7	1 and antibod\$3	US-PGPUB; USPAT	OR	ON	2005/09/22 14:27
L5	0	remove adj anti-hla	US-PGPUB; USPAT	OR	ON	2005/09/22 14:28
L6	16	remov\$ adj anti-hla	US-PGPUB; USPAT	OR	ON	2005/09/22 14:28

L5 ANSWER 4 OF 11 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

TI Adsorption of cytotoxic anti-**HLA** antibodies with **HLA**  
class I immunosorbant beads.

AB In an effort to generate **HLA** immunosorbants to specifically  
remove anti-**HLA** antibodies from sera of highly sensitized  
patients, we purified **HLA** proteins, covalently coupled them onto  
Sepharose, and adsorbed antisera from five patients with narrowly reactive  
cytotoxic anti-**HLA** antibodies and from one patient with broadly  
reactive antibodies. We found that an **HLA**-A2 immunosorbant  
depleted anti-**HLA**-A2 cytotoxic antibodies, but did not deplete  
anti-**HLA**-B7 or anti-**HLA**-B44 cytotoxic antibodies from  
the narrowly reactive patient sera. Patient S.C. developed high PRA (81%)  
with strong cytotoxicity against **HLA**-A1 and -A2 following  
rejection of an **HLA**-A1, -B57 mismatched kidney. We adsorbed his  
sera with five **HLA** immunosorbants including **HLA**-A2 and  
**HLA**-A1,28. We found that the **HLA**-A2 immunosorbant  
depleted antibodies to **HLA**-A2+ and **HLA**  
-B57+ cells but not to **HLA**-A1+ cells, while the **HLA**  
-A1,A28 immunosorbant depleted antibodies to both  
**HLA**-A1+ cells and to the **HLA**-A28 cross-reactive  
**HLA**-A2+ cells. Adsorption was specific for **HLA**-A  
alleles to which the patient was sensitized, since neither **HLA**  
-B-C immunosorbants (containing **HLA**-B7-, -B8, -B13, -B27, or  
-B37 plus **HLA**-C gene products) nor the control immunosorbants  
(bovine serum albumin or diphtheria toxoid) depleted  
serum S.C. of cytotoxic anti-**HLA** antibodies. Our  
results indicate that **HLA** immunosorbants are stable to  
sequential cycles of adsorption and elution, and thus may be of future  
therapeutic value in treatment of sensitized patients.

SO Transplantation, (1990) Vol. 49, No. 5, pp. 925-931.  
ISSN: 0041-1337 CODEN: TRPLAU

AU DeVito L.D.; Sollinger H.W.; Burlingham W.J.

- TI [Protein A immunoadsorption als ein neues apheresis verfahren zur elimination of **HLA** antibodies].  
Die Protein-A-Immunadsorption als ein neues Aphereseverfahren zur Elimination von **HLA**-Antikörpern.
- AB The protein A immunoadsorption allows to **remove antibodies** of the classes IgG, IgM and IgA in special quantities from the **plasma**. IgG subclasses 1, 2 and 4 will be removed for 100% and IgG of class 3 for nearly 80%. For this reason immunoadsorptions are a useful therapeutic method especially for immunological diseases with antibodies of IgG type. The successful use of immunoadsorption in the removal of **HLA** antibodies in patients with acute myeloic leukemia and patients after kidney allograft is reported.
- SO Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine, (1994) 32 360-5.  
Journal code: 9442459. ISSN: 1023-2028.
- AU Schneidewind J; Gliesche T; Sehland D; Ramlow W; Wolfsdorff B; Bast R; Wegener S; Decker S; Schmidt R